OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
June 14, 2018
Recipharm adds inhalation drug manufacturing capacity with the acquisition of Sanofi’s Holmes Chapel, UK site.
June 13, 2018
Cambrex expands its generic API research and development capabilities at its Milan, Italy site.
June 08, 2018
MilliporeSigma targets emerging biotechs with US development center and global grants.
June 01, 2018
Catalent’s GPEx technology was used to develop antibody for anti-methamphetamine clinical study.
Bosch Packaging Technology will introduce its newest R&D device for continuous oral solid dosage production at Achema 2018.
May 24, 2018
In adding a Vanrx Pharmasystems aseptic filling isolator, FUJIFILM adds fill/finish for gene therapies and viral vaccines.
May 16, 2018
Cambrex Corporation has announced facility, equipment, and instrument upgrades at its High Point, NC facility and updated progress on expansions in Cedar City, IA.
Valerius Biopharma will use Catalent’s GPEx technology to produce cell lines for biosimilar drugs.
May 08, 2018
The company received a complete response letter from FDA in response to the biologics license application for a proposed rituximab biosimilar.
May 07, 2018
The data and analytics company reports on the anticipated uptake of Humira (adalimumab) biosimilars in the EU once they are launched in 2018.